CoChat

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

AIMS/HYPOTHESIS: In type 2 diabetes mellitus, heart failure is a frequent, potentially fatal and often forgotten complication. Glucose-lowering agents and adjuvant therapies modify the risk of heart failure. We recently reported that 7.8 years of intensified compared with conventional multifactorial intervention in individuals with type 2 diabetes and microalbuminuria in the Steno-2 study reduced the risk of cardiovascular disease and prolonged life over 21.2 years of follow-up. In this post hoc analysis, we examine the impact of intensified multifactorial intervention on the risk of hospitalisation for heart failure. METHODS: One hundred and sixty individuals were randomised to conventional or intensified multifactorial intervention, using sealed envelopes. The trial was conducted using the Prospective, Randomised, Open, Blinded Endpoints (PROBE) design. After 7.8 years, all individuals were offered intensified therapy and the study continued as an observational follow-up study for an additional 13.4 years. Heart-failure hospitalisations were adjudicated from patient records by an external expert committee blinded for treatment allocation. Event rates were compared using a Cox regression model adjusted for age and sex. RESULTS: Eighty patients were assigned to each treatment group. Ten patients undergoing intensive therapy vs 24 undergoing conventional therapy were hospitalised for heart failure during follow-up. The HR (95% CI) was 0.30 (0.14, 0.64), p = 0.002 in the intensive-therapy group compared with the conventional-therapy group. Including death in the endpoint did not lead to an alternate overall outcome; HR 0.51 (0.34, 0.76), p = 0.001. In a pooled cohort analysis, an increase in plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) during the first two years of the trial was associated with incident heart failure. CONCLUSIONS/INTERPRETATION: Intensified, multifactorial intervention for 7.8 years in type 2 diabetic individuals with microalbuminuria reduced the risk of hospitalisation for heart failure by 70% during a total of 21.2 years of observation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00320008.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-018-4642-y

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 CONSORT diagram showing patient flow throughout the trial. The first 7.8 years were the active intervention period, after which time the randomisation was neutralised and continued as a post-trial observational follow-up study with all remaining patients being offered the same treatment as in the original intensive-therapy group
Fig. 1 CONSORT diagram showing patient flow throughout the trial. The first 7.8 years were the active intervention period, after which time the randomisation was neutralised and continued as a post-trial observational follow-up study with all remaining patients being offered the same treatment as in the original intensive-therapy groupCC BY · PubMed Central
Fig. 2 CIF plot of hospitalisation for heart failure. Dashed line, conventional therapy; solid line, intensive therapy. The unadjusted relative hazard reduction was 69% in the intensive-therapy group. Logrank p = 0.001
Fig. 2 CIF plot of hospitalisation for heart failure. Dashed line, conventional therapy; solid line, intensive therapy. The unadjusted relative hazard reduction was 69% in the intensive-therapy group. Logrank p = 0.001CC BY · PubMed Central
Fig. 3 CIF plots of the secondary outcomes. Dashed line, conventional therapy; solid line, intensive therapy. (a) Heart failure or cardiovascular death. The unadjusted relative hazard reduction was 61% in the intensive-therapy group. Logrank p < 0.001. (b) Heart failure or death from all causes. The unadjusted relative hazard reduction was 48% in the intensive-therapy group. Logrank p = 0.001
Fig. 3 CIF plots of the secondary outcomes. Dashed line, conventional therapy; solid line, intensive therapy. (a) Heart failure or cardiovascular death. The unadjusted relative hazard reduction was 61% in the intensive-therapy group. Logrank p < 0.001. (b) Heart failure or death from all causes. The unadjusted relative hazard reduction was 48% in the intensive-therapy group. Logrank p = 0.001CC BY · PubMed Central
Fig. 4 Transition frequencies from entry to MI, HF and/or death. (a) Intensive-therapy group and (b) conventional-therapy group: arrows terminate at the event and originate from the original state of the patients. The black number at the arrow end is the number with the given event coming from the state at arrow origin. The coloured number in the bottom right corner is the number of patients not progressing from the given state. Example: ten intensive-therapy patients developed HF (pale orange box, Fig. 4a). Eight had no previous MI; two developed HF after previous MI. One developed MI after HF, six died after HF and three ended the observation alive with HF. Twenty-seven patients died without prior MI or HF. In the primary analysis of data from the 21.2 years of follow-up, 26 patients in the intensive-therapy and 29 in the conventional-therapy group were classified as having died from non-CV causes and 12 vs 26 patients died from CV causes, respectively. Thirty-seven patients in the intensive-therapy group and 20 patients in the conventional-therapy group ended follow-up alive and with no incident HF or MI during follow-up. (c) Intensive-therapy group and (d) conventional-therapy group: survival frequencies without MI/HF. Both MI and HF were more frequent in the conventional-therapy group (b) and the difference in HF was not driven primarily by increased MI risk. DM2, type 2 diabetes mellitus; HF, heart failure
Fig. 4 Transition frequencies from entry to MI, HF and/or death. (a) Intensive-therapy group and (b) conventional-therapy group: arrows terminate at the event and originate from the original state of the patients. The black number at the arrow end is the number with the given event coming from the state at arrow origin. The coloured number in the bottom right corner is the number of patients not progressing from the given state. Example: ten intensive-therapy patients developed HF (pale orange box, Fig. 4a). Eight had no previous MI; two developed HF after previous MI. One developed MI after HF, six died after HF and three ended the observation alive with HF. Twenty-seven patients died without prior MI or HF. In the primary analysis of data from the 21.2 years of follow-up, 26 patients in the intensive-therapy and 29 in the conventional-therapy group were classified as having died from non-CV causes and 12 vs 26 patients died from CV causes, respectively. Thirty-seven patients in the intensive-therapy group and 20 patients in the conventional-therapy group ended follow-up alive and with no incident HF or MI during follow-up. (c) Intensive-therapy group and (d) conventional-therapy group: survival frequencies without MI/HF. Both MI and HF were more frequent in the conventional-therapy group (b) and the difference in HF was not driven primarily by increased MI risk. DM2, type 2 diabetes mellitus; HF, heart failureCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 91

Metadata

Authors
Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H.-H., & Pedersen, O.
Affiliations
  • University of Southern Denmark (DK)
  • University of Copenhagen (DK)
  • Rigshospitalet (DK)
Corresponding author
Pedersen, Oluf
Venue
Diabetologia
Published
2018-05-30
Volume
61
Issue
8
Pages
1724-1733
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W2806147248
Cited by
86
References
41
Citations by year
2026: 5 · 2025: 7 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 7
FWCI
10.15
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Diabetologia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes, heart failure, microalbuminuria, heart failure hospitalization, Steno-2 trial, N-terminal pro-brain natriuretic peptide, long-term follow-up, cardiovascular risk reduction
MeSH terms
Aged, Albuminuria, Denmark, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypoglycemic Agents, Male, Middle Aged, Prospective Studies, Risk, Time Factors, Proportional Hazards Models, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. https://app.cochat.ai/papers/10.1007/s00125-018-4642-y
The paper
Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H.-H., & Pedersen, O. (2018). Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study. Diabetologia. https://doi.org/10.1007/s00125-018-4642-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.